Luke A. Potter

Luke A. Potter

Auto-generated profile, based on publicly available information

Luke A. Potter

Institutional Research Core Program - Biological Data Science Core, University of Alabama at Birmingham, Birmingham, AL, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
CHChae‐Myeong Ha
Chae‐Myeong Ha
SBSayan Bakshi
Sayan Bakshi
MBManoja K. Brahma
Manoja K. Brahma
LPLuke A. Potter
Luke A. Potter
SCSamuel F. Chang
Samuel F. Chang
AWAdam R. Wende
Adam R. Wende
Background: Lifestyle and metabolic diseases influence the severity and pathogenesis of cardiovascular disease through numerous mechanisms, including regulation via posttranslational modifications. A specific posttranslational modification, the addition of O ‐linked β‐ N acetylglucosamine ( O ‐GlcNAcylation), has been implicated in molecular mechanisms of both physiological and pathologic adaptations. The current study aimed to test the hypothesis that in cardiomyocytes, sustained protein O ‐GlcNAcylation contributes to cardiac adaptations, and its progression to pathophysiology. Methods and Results: Using a naturally occurring dominant‐negative O ‐GlcNAcase (dnOGA) inducible cardiomyocyte‐specific overexpression transgenic mouse model, we induced dnOGA in 8‐ to 10‐week‐old mouse hearts. We examined the effects of 2‐week and 24‐week dnOGA overexpression, which progressed to a 1.8‐fold increase in protein O‐ GlcNAcylation. Two‐week increases in protein O ‐GlcNAc levels did not alter heart weight or function; however, 24‐week increases in protein O ‐GlcNAcylation led to cardiac hypertrophy, mitochondrial dysfunction, fibrosis, and diastolic dysfunction. Interestingly, systolic function was maintained in 24‐week dnOGA overexpression, despite several changes in gene expression associated with cardiovascular disease. Specifically, mRNA‐sequencing analysis revealed several gene signatures, including reduction of mitochondrial oxidative phosphorylation, fatty acid, and glucose metabolism pathways, and antioxidant response pathways after 24‐week dnOGA overexpression. Conclusions: This study indicates that moderate increases in cardiomyocyte protein O ‐GlcNAcylation leads to a differential response with an initial reduction of metabolic pathways (2‐week), which leads to cardiac remodeling (24‐week). Moreover, the mouse model showed evidence of diastolic dysfunction consistent with a heart failure with preserved ejection fraction. These findings provide insight into the adaptive versus maladaptive responses to increased O‐ GlcNAcylation in heart.

1 July 2023 in Physiological Genomics
Verified
Journal Article
Closed access
LPLuke A. Potter
Luke A. Potter
CTCarlos A. Toro
Carlos A. Toro
LHLauren Harlow
Lauren Harlow
KLKaleen M. Lavin
Kaleen M. Lavin
CCChristopher P. Cardozo
Christopher P. Cardozo
ZGZachary Graham
Zachary Graham
This is the first study to describe the multiome of skeletal muscle paralyzed by a spinal cord injury (SCI) in mice across the acute and subacute timeframe after injury. We show large-scale changes in the metabolome and transcriptome at 7 days post-injury compared with 28 days. Furthermore, we show that the alkaloid boldine was able to prevent SCI-induced changes in muscle glucose and free amino acid levels at 7 days, but not 28 days, after SCI.

1 May 2021 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
PDF file
MPMark E. Pepin
Mark E. Pepin
CHChae-Myeong Ha
Chae-Myeong Ha
LPLuke A. Potter
Luke A. Potter
SBSayan Bakshi
Sayan Bakshi
JBJoseph P. Barchue
Joseph P. Barchue
AWAdam R. Wende
Adam R. Wende
Heart failure (HF) is a multifactorial syndrome that remains a leading cause of worldwide morbidity. Despite its high prevalence, only half of patients with HF respond to guideline-directed medical management, prompting therapeutic efforts to confront the molecular underpinnings of its heterogeneity. In the current study, we examined epigenetics as a yet unexplored source of heterogeneity among patients with end-stage HF. Specifically, a multicohort-based study was designed to quantify cardiac genome-wide cytosine-p-guanine (CpG) methylation of cardiac biopsies from male patients undergoing left ventricular assist device (LVAD) implantation. In both pilot (n = 11) and testing (n = 31) cohorts, unsupervised multidimensional scaling of genome-wide myocardial DNA methylation exhibited a bimodal distribution of CpG methylation found largely to occur in the promoter regions of metabolic genes. Among the available patient attributes, only categorical self-identified patient race could delineate this methylation signature, with African American (AA) and Caucasian American (CA) samples clustering separately. Because race is a social construct, and thus a poor proxy of human physiology, extensive review of medical records was conducted, but ultimately failed to identify covariates of race at the time of LVAD surgery. By contrast, retrospective analysis exposed a higher all-cause mortality among AA (56.3%) relative to CA (16.7%) patients at 2 yr following LVAD placement (P = 0.03). Geocoding-based approximation of patient demographics uncovered disparities in income levels among AA relative to CA patients. Although additional studies are needed, the current analysis implicates cardiac DNA methylation as a previously unrecognized indicator of socioeconomic disparity in human heart failure outcomes. NEW & NOTEWORTHY A bimodal signature of cardiac DNA methylation in heart failure corresponds with racial differences in all-cause mortality following mechanical circulatory support. Racial differences in promoter methylation disproportionately affect metabolic signaling pathways. Socioeconomic factors are associated with racial differences in the cardiac methylome among men with end-stage heart failure. Listen to this article’s corresponding podcast at https://ajpheart.podbean.com/e/racial-socioeconomic-determinants-of-the-cardiac-epigenome/.

6 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SCSamuel F. Chang
Samuel F. Chang
CHChae‐Myeong Ha
Chae‐Myeong Ha
MBManoja K. Brahma
Manoja K. Brahma
LPLuke A. Potter
Luke A. Potter
MRMahima S. Reddy
Mahima S. Reddy
AWAdam R. Wende
Adam R. Wende
Background: The observation that patients with diabetes always under tight‐glycemic control consistently show better cardiovascular disease outcomes compared with patients who transition to tight‐glycemic control after prior conventional glycemic control led to the concept of metabolic memory. Mechanisms such as epigenetics possibly mediate the lasting metabolic memory effects, without a known mechanism. Increased cardiac protein posttranslational O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification is implicated in cardiac remodeling observed in diabetes, and our previous work shows that chronically elevated cardiomyocyte O‐GlcNAc causes adverse cardiac changes. We hypothesized that transiently increased cardiomyocyte O‐GlcNAcylation leads to exacerbated adverse cardiac remodeling after subsequent pressure‐overload. Methods: Using an inducible cardiomyocyte specific, dominant‐negative O‐GlcNAcase (dnOGAh) mouse and single transgenic littermate controls (Con), we induced O‐GlcNAc levels for 2 weeks (ON), followed by a 2‐week washout (OFF); mice then underwent transverse‐aortic constriction (TAC) or Sham surgery followed by comprehensive physiological and molecular assessments. Results: We observed the expected cardiac remodeling in TAC groups, including decreased cardiac function, and increased hypertrophy and fibrosis. Moreover, these pathologic measures were exacerbated in the ON/OFF‐TAC versus Con‐TAC mice; additionally, transcriptomic analysis of left ventricle tissue from each experimental group showed pathways which supported our fibrosis, hypertrophy and functional results of exacerbated cardiac remodeling, and revealed potential novel molecular pathways underlying this pathologic remodeling. Conclusions: We observed exacerbated cardiac pathology between ON/OFF‐TAC versus Con‐TAC groups supporting the concept of “O‐GlcNAc memory” as a component of metabolic memory. Moreover, transcriptomic analysis provides insight into potential molecular pathways underpinning this metabolic/O‐GlcNAc memory such as Ccn2 /CTGF‐driven fibrosis, and/or Nox4 ‐driven oxidative stress.

4 March 2026 in Epigenetics
Verified
Journal Article
Open access
SBSayan Bakshi
Sayan Bakshi
SCSamuel F. Chang
Samuel F. Chang
LPLuke A. Potter
Luke A. Potter
ZSZhihuan Sun
Zhihuan Sun
CHChae-Myeong Ha
Chae-Myeong Ha
AWAdam R. Wende
Adam R. Wende
Clinically prior hyperglycemia may lead to long-lasting adverse cardiovascular effects, a process referred to as 'glycemic memory.' Epigenetic modifications, specifically DNA methylation changes, may play a key role in this phenomenon. This study investigated if prior high glucose delivery to cardiomyocytes, led to worsened cardiovascular effects upon pressure overload and to ascertain the gene expression and corresponding DNA methylation signatures linked to glycemic memory. Using inducible and cardiomyocyte-specific glucose transporter 4 (GLUT4) overexpressing mice. We induced glucose delivery for 2 weeks, then returned to basal uptake for 2 weeks, followed by sham or transverse aortic constriction (TAC) surgery as a secondary stress. Mice were followed for an additional 8 weeks and assessed for contractile function, cellular remodeling, and molecular changes. TAC led to an exacerbated hypertrophic response and cardiac dysfunction in the transgenic mice. Subsequent analysis identified molecular changes akin to heart failure, worsened cardiac fibrosis, and oxidative stress. Using bulk RNA-sequencing and reduced representation bisulfite sequencing, we discovered differential gene expression and DNA methylation signatures that persisted even after cellular glucose levels reverted to normal. Significant changes across both expression and methylation-identified enriched pathways related to adverse cardiac events, supporting a glycemic memory response. Glycemic memory led to cardiac structural and functional exacerbation, mimicking heart failure, when subjected to a secondary stress. Our data identified transcriptome, and preliminary DNA methylome changes which may potentially be molecular signatures of future therapeutic targets associated with this heart failure susceptibility resulting from enhanced glucose delivery.

30 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ODOlivia R. Drake
Olivia R. Drake
CFCaroline M. Fiore
Caroline M. Fiore
EJEmily T. Jorgensen
Emily T. Jorgensen
CNCatherine E. Newman
Catherine E. Newman
LPLuke A. Potter
Luke A. Potter
JDJeremy Day
Jeremy Day
Summary: A longstanding paradox in striatal circuit architecture is that opioid reward depends on μ-opioid receptors (µORs) in nucleus accumbens medium spiny neurons (MSNs), yet µOR function is not explained by the canonical D1/direct and D2/indirect pathway organization. Here, we identify a rare MSN population marked by Chst9 that exhibits exceptionally high expression of the µOR and is conserved across species. Notably, Chst9-MSNs comprise a specialized indirect pathway striatal neuron subtype that is molecularly and spatially distinct from canonical striatal populations. Opioids robustly silence Chst9-MSNs, and selective deletion of Oprm1 from this population abolishes fentanyl-conditioned place preference. These findings establish Chst9-MSNs as a critical substrate for opioid reward and define a new cellular framework for therapies targeting opioid use disorder.